COMPANY PROFILE

Junhe League

Explore full profile

Recombinant protein drug developer

Hangzhou, ChinaFounded 2020Biotech & Life Sciences

Valuation $100–250M Last recorded · 2024

Total funding $50–100M Disclosed equity funding

At a glance

Status: Operational
Founded: 2020
Headquarters: Hangzhou, China
Open positions: None listed
Dealroom signal: 26.7/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b

News, research, reports and resources connected to this company by Dealroom

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Sep 2024	$28M	$110M	Oriza Holdings · SoYoung Technology · SDIC Unity Capital · Hongsheng Investment Management	↗
SERIES AOther financing	Oct 2022	$28M	$110M	Zhonghe Oppo · Focus Fund · Guangdian Capital · Tonghua SDIC	↗

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SMSuperluminal MedicinesGenerative biology and chemistry company revolutionizing the speed and accuracy of how medicine is created	Boston, United States	Operational	60	$213M	$240M
NTNexo TherapeuticsUses a combination of covalent ligand discovery and chemical biology to develop new cancer therapies	Golden, United States	Operational
BTBiolexis TherapeuticsReimagines drug discovery with it's proprietary FIELDS Technology	Sandy, United States	Operational
BBBigHat BiosciencesProtein therapeutics company that develops an antibody design platform guided by artificial intelligence	San Carlos, United States	Operational
HPHerantis PharmaInnovative biotech company developing disease modifying therapies for Parkinson’s disease	Helsinki, Finland	Operational
GTGain TherapeuticsPreclinical stage biotech company developing a class of next generation brain-penetrant non-competitive pharmacological chaperones for the treatment of devastating diseases using the proprietary SEE-Tx® technology	Lugano, Switzerland	Operational
MTMiNA TherapeuticsA platform that enables the development of new medicines that restore normal function to patients’ cells	London, United Kingdom	Operational
ANAnagenexBiotechnology company building a novel platform for drug discovery focusing on difficult targets	San Francisco, United States	Operational